Overseas Treatment of Latent Tuberculosis Infection in US-Bound Immigrants.

AmeraKhan; Christina RPhares; Hoang LanPhuong; Dang Thi KieuTrinh; HaPhan; CindyMerrifield; Phan Thi HongLe; Quach Thi KimLien; Sooc NgocLan; Phan Thi KimThoa; +8 more... Le Tran MinhThu; TiffanyTran; CucTran; Lucy Platt ORCID logo; Susan AMaloney; Nguyen VietNhung; PayamNahid; John EOeltmann; (2022) Overseas Treatment of Latent Tuberculosis Infection in US-Bound Immigrants. Emerging Infectious Diseases, 28 (3). pp. 582-590. ISSN 1080-6040 DOI: 10.3201/eid2803.212131
Copy

Seventy percent of tuberculosis (TB) cases in the United States occur among non-US-born persons; cases usually result from reactivation of latent TB infection (LTBI) likely acquired before the person's US arrival. We conducted a prospective study among US immigrant visa applicants undergoing the required overseas medical examination in Vietnam. Consenting applicants >15 years of age were offered an interferon-γ release assay (IGRA); those 12-14 years of age received an IGRA as part of the required examination. Eligible participants were offered LTBI treatment with 12 doses of weekly isoniazid and rifapentine. Of 5,311 immigrant visa applicants recruited, 2,438 (46%) consented to participate; 2,276 had an IGRA processed, and 484 (21%) tested positive. Among 452 participants eligible for treatment, 304 (67%) initiated treatment, and 268 (88%) completed treatment. We demonstrated that using the overseas medical examination to provide voluntary LTBI testing and treatment should be considered to advance US TB elimination efforts.



picture_as_pdf
Khan_etal_2022_Overseas-treatment-of-latent-tuberculosis.pdf
subject
Published Version
Available under Creative Commons: 4.0

View Download

Explore Further

Read more research from the creator(s):

Find work associated with the faculties and division(s):

Find work from this publication: